NBIX
$91.09
Neurocrine Bioscienc
($8.41)
(8.45%)
NBIX
Earnings Whisper ®
N/A
4th Quarter December 2018
Consensus:  $0.12
Revenue:  N/A
Monday
Feb 4
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NBIX reports earnings?
Beat
Meet
Miss

Where is NBIX's stock price going from here?
Up
Flat
Down
Stock chart of NBIX
Analysts
Summary of analysts' recommendations for NBIX
Score
Grade
Pivots
Resistance
$109.09
$107.03
$103.27

$101.21

Support
$97.45
$95.39
$91.63
Tweet
Growth
Description
Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
Peers
BiogenGilead SciencesAmgenBluebird BioSeattle GeneticsQiagen N.V.BioCryst PharmaceuticalsRepligenSangamo TherapeuticsBio-Techne